IP Library Granted Patent US 10,398,884
Granted Patent B2
US 10,398,884 · App. 15/410,219 · Granted Sep 3, 2019

Cerebrospinal fluid purification system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,398,884
App. No.
15/410,219
Granted
Sep 3, 2019
Kind
B2
Abstract

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.

Claims (21)

1. A method for ameliorating a symptom of meningitis in a patient, said method comprising:

selecting a patient having a symptom of meningitis;

removing cerebrospinal fluid from a first location in a lumbar cerebrospinal fluid space of the patient;

removing at a flow rate a causative agent from the removed cerebrospinal fluid, thereby conditioning the cerebrospinal fluid; and

returning the conditioned cerebrospinal fluid to the patient at a second location in a cervical cerebrospinal fluid space, a thoracic cerebrospinal fluid space, or a ventricle of the patient, wherein the cerebrospinal fluid is returned to the patient at substantially the same flow rate at which it is removed;

wherein the removing and returning steps are performed concurrently using one or more catheters, each catheter comprising one or more lumens.

2. A method as in claim 1 , wherein the one or more catheters comprises a single catheter comprising a first lumen with a first proximal port at the first location and a second lumen having a second distal port at the second location during at least a portion of a conditioning treatment.

3. A method as in claim 1 , wherein the one or more catheters comprises a first catheter inserted at the first location and a second catheter inserted at the second location during at least a portion of a conditioning treatment.

4. A method as in claim 3 , wherein the first catheter and the second catheter each comprise a single lumen.

5. A method as in claim 1 , wherein the step of removing at a flow rate includes removing at least one of a bacterial, a viral, and a fungal agent.

6. A method as in claim 1 , wherein the flow rate is in a range from 0.04 ml/min to 30 ml/min.

7. A method as in claim 6 , wherein a volume of cerebrospinal fluid removed from the patient never exceeds 40 ml.

8. A method as in claim 1 , wherein the second location is in the cervical cerebrospinal fluid space.

9. A method as in claim 1 , wherein the second location is in the ventricle of a brain.

10. A method as in claim 1 , wherein the second location is in a thoracic cerebrospinal fluid space.

11. A method as in claim 1 , wherein flow directions of removing and returning cerebrospinal fluid are periodically reversed so that CSF is returned to the first location and removed from the second location during a portion of the treatment.

12. A method as in claim 11 , wherein the flow reversal is a pulse to dislodge debris from removal or return ports.

13. A method as in claim 1 , further comprising mixing the conditioned cerebrospinal fluid with endogenous cerebrospinal fluid as the conditioned cerebrospinal fluid is returned to the cerebrospinal fluid space.

14. A method as in claim 13 , wherein mixing comprises inducing a turbulent flow as the conditioned cerebrospinal fluid is returned.

15. A method as in claim 1 , wherein the conditioning comprises one or more separation processes selected from the group consisting of biospecific affinity, immunoaffinity, cationic exchange, anionic exchange, hydrophobicity, and size exclusion.

16. A method as in claim 1 , wherein the conditioning step is performed externally to the patient's body.

Assignments (4)
RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 054795/0607, SUPPLEMENTAL PATENT SECURITY AGREEMENT - REAL/FRAME 056240/0147 AND ASSIGNMENT ID: 885388 Recorded Oct 1, 2025
From: TEXAS CAPITAL BANK, AS AGENT
To: MINNETRONIX MEDICAL, INC.
Reel/Frame 073434/0838 →
PARTIAL RELEASE OF PATENT SECURITY AGREEMENT - REEL 054795 FRAME 0607; AND REEL 056240 FRAME 0147 Recorded Jun 10, 2025
From: TEXAS CAPITAL BANK, AS ADMINISTRATIVE AGENT
To: MINNETRONIX, INC.; MINNETRONIX NEURO, INC. (F/K/A NEUROFLUIDICS, INC.)
Reel/Frame 071588/0015 →
ASSIGNMENT OF SECURITY INTEREST IN PATENT COLLATERAL RECORDED ON REEL 054795 FRAME 0607 AND SUPPLEMENTAL PATENT SECURITY AGREEMENT RECORDED ON REEL 056240 FRAME 0147 Recorded Mar 13, 2025
From: FIRST HORIZON BANK
To: TEXAS CAPITAL BANK, AS SUCCESSOR AGENT
Reel/Frame 073460/0969 →
SECURITY INTEREST Recorded Jan 4, 2021
From: MINNETRONIX MEDICAL, INC.; MINNETRONIX NEURO, INC.
To: FIRST HORIZON BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 054795/0607 →